Catalent
CTLT
$55.92
Share price
0.22%
Change (1 day)
19.11%
Change (1 year)
Categories
Catalent is an American pharmaceutical contract research and development company.
Catalent (CTLT) - Total debt
Total debt on the balance sheet as of December 2023 : $5.01 B
According to Catalent's latest financial reports the company's total debt is $5.01 B. A company’s total debt is the sum of all current and non-current debts.
Catalent - Total debt on balance sheet (from 2013 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2023-06-30 | $4.86 B | 15.28% |
| 2022-06-30 | $4.21 B | 29.44% |
| 2021-06-30 | $3.25 B | 7.39% |
| 2020-06-30 | $3.03 B | 2.49% |
| 2019-06-30 | $2.95 B | 8.75% |
| 2018-06-30 | $2.72 B | 30.85% |
| 2017-06-30 | $2.07 B | 11.78% |
| 2016-06-30 | $1.86 B | -1.08% |
| 2015-06-30 | $1.88 B | -30.61% |
| 2014-06-30 | $2.71 B | 0.71% |
| 2013-06-30 | $2.69 B | 0.3% |
| 2012-06-30 | $2.68 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Supernus Pharmaceuticals
SUPN | $41.52 M | -99.17% | 🇺🇸 USA |
 Jazz Pharmaceuticals JAZZ | $5.79 B | 15.51% | 🇮🇪 Ireland |
 Aerie Pharmaceuticals AERI | $0.33 B | -93.28% | 🇺🇸 USA |
 Intercept Pharmaceuticals
ICPT | $0.22 B | -95.54% | 🇺🇸 USA |